{
    "root": "62443ae3-6500-41b3-977b-582838a2ccd5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "azithromycin",
    "value": "20250502",
    "ingredients": [
        {
            "name": "AZITHROMYCIN DIHYDRATE",
            "code": "5FD1131I7S"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        }
    ],
    "indications": "azithromycin tablets macrolide antibacterial indicated mild moderate infections caused designated , susceptible bacteria : • acute bacterial exacerbations chronic bronchitis adults ( 1.1 ) • acute bacterial sinusitis adults ( 1.1 ) • uncomplicated skin skin structure infections adults ( 1.1 ) • urethritis cervicitis adults ( 1.1 ) • genital ulcer disease men ( 1.1 ) • acute otitis media pediatric patients ( 6 months age older ) ( 1.2 ) • community-acquired pneumonia adults pediatric patients ( 6 months age older ) ( 1.1 , 1.2 ) • pharyngitis/tonsillitis adults pediatric patients ( 2 years age older ) ( 1.1 , 1.2 ) limitation : azithromycin used patients pneumonia judged inappropriate oral therapy moderate severe illness risk factors . ( 1.3 ) reduce development drug-resistant bacteria maintain effectiveness azithromycin tablets antibacterial drugs , azithromycin tablets used treat infections proven strongly suspected caused susceptible bacteria . ( 1.4 )",
    "contraindications": "• adult patients ( 2.1 ) infection recommended dose/duration therapy community-acquired pneumonia ( mild severity ) pharyngitis/tonsillitis ( second-line therapy ) skin/skin structure ( uncomplicated ) 500 mg single dose day 1 , followed 250 mg daily days 2 5. acute bacterial exacerbations chronic bronchitis ( mild moderate ) 500 mg single dose day 1 , followed 250 mg daily days 2 5 500 mg daily 3 days . acute bacterial sinusitis 500 mg daily 3 days . genital ulcer disease ( chancroid ) non-gonococcal urethritis cervicitis one single 1 gram dose . gonococcal urethritis cervicitis one single 2 gram dose . • pediatric patients ( 2.2 ) infection recommended dose/duration therapy acute otitis media ( 6 months age older ) 30 mg/kg single dose 10 mg/kg daily 3 days 10 mg/kg single dose day 1 followed 5 mg/kg/day days 2 5. acute bacterial sinusitis ( 6 months age older ) 10 mg/kg daily 3 days . community-acquired pneumonia ( 6 months age older ) 10 mg/kg single dose day 1 followed 5 mg/kg daily days 2 5. pharyngitis/tonsillitis ( 2 years age older ) 12 mg/kg daily 5 days .",
    "warningsAndPrecautions": "azithromycin tablets usp supplied following strengths package configurations : azithromycin tablets usp , 250 mg supplied pink , oval shaped film-coated tablets , engraved `` lu `` one side `` l04 `` side containing azithromycin dihydrate equivalent 250 mg azithromycin usp . cartons 50 film-coated tablets ( 10 film-coated tablets blister pack x 5 ) , ndc 0904-7350-06 cartons 100 film-coated tablets ( 10 film-coated tablets blister pack x 10 ) , ndc 0904-7350-61 azithromycin tablets usp , 500 mg supplied pink , oval shaped film-coated tablets , engraved `` lu `` one side `` l05 `` side containing azithromycin dihydrate usp equivalent 500 mg azithromycin usp . cartons 30 film-coated tablets ( 10 film-coated tablets blister pack x 3 ) , ndc 0904-7351-04 store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "• patients known hypersensitivity azithromycin , erythromycin , macrolide ketolide . ( 4.1 ) • patients history cholestatic jaundice/hepatic dysfunction associated prior azithromycin . ( 4.2 )",
    "indications_original": "Azithromycin tablets are a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: • Acute bacterial exacerbations of chronic bronchitis in adults ( 1.1 ) • Acute bacterial sinusitis in adults ( 1.1 ) • Uncomplicated skin and skin structure infections in adults ( 1.1 ) • Urethritis and cervicitis in adults ( 1.1 ) • Genital ulcer disease in men ( 1.1 ) • Acute otitis media in pediatric patients (6 months of age and older) ( 1.2 ) • Community-acquired pneumonia in adults and pediatric patients  (6 months of age and older) ( 1.1 , 1.2 ) • Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) ( 1.1 , 1.2 ) Limitation of Use: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 )",
    "contraindications_original": "• Adult Patients ( 2.1 ) Infection Recommended Dose/Duration of Therapy Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5. Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. Genital ulcer disease (chancroid) Non-gonococcal urethritis and cervicitis One single 1 gram dose. Gonococcal urethritis and cervicitis One single 2 gram dose. • Pediatric Patients ( 2.2 ) Infection Recommended Dose/Duration of Therapy Acute otitis media (6 months of age and older) 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5. Acute bacterial sinusitis (6 months of age and older) 10 mg/kg once daily for 3 days. Community-acquired pneumonia (6 months of age and older) 10 mg/kg as a single dose on Day 1 followed by   5 mg/kg once daily on Days 2 through 5. Pharyngitis/tonsillitis (2 years of age and older) 12 mg/kg once daily for 5 days.",
    "warningsAndPrecautions_original": "Azithromycin tablets USP are supplied in the following strengths and package configurations:\n                  Azithromycin tablets USP, 250 mg are supplied as pink, oval shaped film-coated tablets, engraved with \"LU\" on one side and \"L04\" on the other side containing azithromycin dihydrate equivalent to 250 mg of azithromycin USP.\n                  Cartons of 50 film-coated tablets (10 film-coated tablets each blister pack x 5), NDC 0904-7350-06\n                  Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7350-61\n                  Azithromycin tablets USP, 500 mg are supplied as pink, oval shaped film-coated tablets, engraved with \"LU\" on one side and \"L05\" on the other side containing azithromycin dihydrate USP equivalent to 500 mg of azithromycin USP.\n                  Cartons of 30 film-coated tablets (10 film-coated tablets each blister pack x 3), NDC 0904-7351-04\n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "• Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. ( 4.1 ) • Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. ( 4.2 )"
}